CAS: 83207-58-3; (2R,3R,4S,5S,6R)-2-(((2Ar,3R,4S,5As,5Bs,7S,7Ar,9S,11Ar,12As)-4-Hydroxy-3-((2S,5R)-5-(2-Hydroxypropan-2-yl)-2-Methyltetrahydrofuran-2-yl)-2A,5A,8,8-Tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-Trihydroxytetrahydro-2H-Pyran-2-yl)Oxy)Hexadecahydrocyclopenta[a]Cyclopr

该化合物是一种生物活性沙邦素化合物,产自传统药草Astragalus membranaceus,其特点是环甲烷型三角锥体结构,分子式为C41H68O14,分子重量为784.97克/摩尔.该化合物具有显著的药理特性,包括抗氧化剂,抗炎和抗成瘾作用,主要归因于它调节线粒体功能和减少氧化性压力的能力.Astragaloside A在心血管保护,...

英文名称(2R,3R,4S,5S,6R)-2-(((2Ar,3R,4S,5As,5Bs,7S,7Ar,9S,11Ar,12As)-4-Hydroxy-3-((2S,5R)-5-(2-Hydroxypropan-2-yl)-2-Methyltetrahydrofuran-2-yl)-2A,5A,8,8-Tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-Trihydroxytetrahydro-2H-Pyran-2-yl)Oxy)Hexadecahydrocyclopenta[a]Cyclopr
中文名称黄芪甲苷
IUPAC名称(2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
其它别名Astragaloside A; Astragaloside-A; Cyclosiversioside F; Astramembrannin I; Astragalin A; Astragaloside Iv; (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-Hydroxy-15-[(2S,5R)-5-(2-Hydroxypropan-2-yl)-2-Methyloxolan-2-Yl]-7,7,12
CAS编号83207-58-3
MFCD编号:MFCD00210476
FDA UNII编号:3A592W8XKE
分子式:C41H68O14
分子量:784.98
产品CID: 1820876
产品分类生物化工

相似结构搜索
InChIKey: QMNWISYXSJWHRY-AUJDEUPOSA-N
QMNWISYXSJWHRY-APZLXCBQNA-N…
计算化学: 氢键受体数14.0氢键供体数9.0可旋转键数7.0

物理性质

熔点284-286 °C
沸点895.7±65.0 °C at 760 mmHg
闪点495.5±34.3 °C
密度1.4±0.1 g/cm3
pKa:12.91±0.70(预测)
PSA:228.22
LogP:1.96
折射率1.621
蒸汽压0.0±0.6 mmHg at 25°C
溶解性DMF: 20 mg/mL; DMSO: 30 mg/mL; DMSO:Pbs(Ph7.2) (1:1): 0.5 mg/mL
外观形态结晶性固体
储存条件在惰性气体(氮气或氩气)下 2-8°C

MSDS等安全信息

警示词Warning
危险描述H302-H315-H319-H335-
防范说明P261-P305+P351+P338-
危险品标志Xi
安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body

上下游产品

合成工艺路线路线简述

其他信息查阅

浙江圣氏生物科技有限公司

网址: http://www.gegejian.com
电话: 0086（572）5018368👤

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

成都科程生物科技开发有限公司

网址: http://www.cogon-chem.com
电话: 028-85171192👤

⚠️ 未注册 · 未认证企业

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献

参考文献:10.1159/000121335
摘要:Xu XL, Chen XJ, Ji H, Li P, Bian YY, Yang D, Xu JD, Bian ZP, Zhang JN. Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase. Pharmacology. 2008;81(4):325–32. doi: 10.1159/000121335.
参考文献:10.1177/1535370214532597
摘要:Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH, Zhang XM, Peng W, Cai H. Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro. Exp Biol Med (Maywood). 2014 Oct;239(10):1310–24. doi: 10.1177/1535370214532597.
参考文献:10.1007/s10753-015-0272-4
摘要:Chen T, Wang R, Jiang W, Wang H, Xu A, Lu G, Ren Y, Xu Y, Song Y, Yong S, Ji H, Ma Z. Protective Effect of Astragaloside IV Against Paraquat-Induced Lung Injury in Mice by Suppressing Rho Signaling. Inflammation. 2016 Feb;39(1):483–92. doi: 10.1007/s10753-015-0272-4.
参考文献:10.1002/bmc.3941
摘要:Shao Y, Zhang W, Tong L, Huang J, Li D, Nie W, Zhu Y, Li Y, Lu T. Simultaneous determination of eight bioactive components of Qishen Yiqi dripping pills in rat plasma using UFLC-MS/MS and its application to a pharmacokinetic study. Biomed Chromatogr. 2017 Aug;31(8). doi: 10.1002/bmc.3941.
参考文献:10.1080/10715762.2017.1290233
摘要:Dong H, Guo H, Liang Y, Wang X, Niu Y. Astragaloside IV synergizes with ferulic acid to suppress hepatic stellate cells activation in vitro. Free Radic Res. 2017 Feb;51(2):167–78. doi: 10.1080/10715762.2017.1290233.